United States Food Administration

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022

Retrieved on: 
Thursday, November 24, 2022

Recorded total net revenue of $5.3 million during the quarter ended September 30, 2022 compared to $4.9 million for the quarter ended September 30, 2021 and;

Key Points: 
  • Recorded total net revenue of $5.3 million during the quarter ended September 30, 2022 compared to $4.9 million for the quarter ended September 30, 2021 and;
    Recorded total net revenue from the sale of AGGRASTATof $3.1 million during the quarter ended September 30, 2022 compared to $2.9 million for the quarter ended September 30, 2021 and;
    Recorded total net revenue from the sale of ZYPITAMAGof $434,000 during the quarter ended September 30, 2022 compared to $388,000 for the quarter ended September 30, 2021 and;
    Recorded total net revenue from the Marley Drugbusiness of $1.8 million during the quarter ended September 30, 2022 compared to $1.6 million for the quarter ended September 30, 2021 and;
    Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended September 30, 2022 was $1.4 million compared to adjusted EBITDA of $282,000 for the quarter ended September 30, 2021 and;
    Net income for the quarter ended September 30, 2022 was $1.1 million or $0.11 per share compared to a net loss of $946,000 or $0.09 per share for the quarter ended September 30, 2021.
  • ZYPITAMAGcontributed $434,000 of revenue for the quarter ended September 30, 2022 compared to $388,000 for the quarter ended September 30, 2021.
  • The Marley Drug business contributed $1.8 million of revenue during the quarter ended September 30, 2022 compared to $1.6 million for the quarter ended September 30, 2021.
  • Adjusted EBITDA for the three months ended September 30, 2022 was $1.4 million compared to $282,000 for the three months ended September 30, 2021.

MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022

Retrieved on: 
Thursday, November 17, 2022

Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

Key Points: 
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.
  • A recording of the call will be available following the event at the Company's website.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks of Medicure International Inc.

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022

Retrieved on: 
Wednesday, August 24, 2022

Recorded total net revenue of $5.7 million during the quarter ended June 30, 2022 compared to $5.1 million for the quarter ended June 30, 2021 and;

Key Points: 
  • Recorded total net revenue of $5.7 million during the quarter ended June 30, 2022 compared to $5.1 million for the quarter ended June 30, 2021 and;
    Recorded total net revenue from the sale of AGGRASTAT of $2.9 million during the quarter ended June 30, 2022 compared to $2.8 million for the quarter ended June 30, 2021 and;
    Recorded total net revenue from the sale of ZYPITAMAG of $1.1 million during the quarter ended June 30, 2022 compared to $403,000 for the quarter ended June 30, 2021 and;
    Recorded total net revenue from the Marley Drug business of $1.8 million during the quarter ended June 30, 2022 compared to $1.9 million for the quarter ended June 30, 2021 and;
    Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended June 30, 2022 was negative $210,000 compared to adjusted EBITDA of $158,000 for the quarter ended June 30, 2021 and;
    Net loss for the quarter ended June 30, 2022 was $683,000 compared to a net loss of $639,000 for the quarter ended June 30, 2021, primarily due to an increased investment in research in development of $1.3 million for the quarter ended June 30, 2022 compared to $705,000 for the quarter ended June 30, 2021.
  • ZYPITAMAG contributed $1.1 million of revenue for the quarter ended June 30, 2022 compared to $403,000 for the quarter ended June 30, 2021.
  • The Marley Drug business contributed $1.8 million of revenue during the quarter ended June 30, 2022 compared to $1.9 million for the quarter ended June 30, 2021.
  • Adjusted EBITDA for the three months ended June 30, 2022 was negative $210,000 compared to $158,000 for the three months ended June 30, 2021.

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

Retrieved on: 
Wednesday, August 17, 2022

Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

Key Points: 
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.
  • A recording of the call will be available following the event at the Company's website.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks of Medicure International Inc.

MEDICURE ANNOUNCES RESULTS OF 2022 AGM

Retrieved on: 
Monday, June 20, 2022

In addition, the shareholders re-appointed Ernst & Young LLP, Chartered Accountants, as auditor of the Company.

Key Points: 
  • In addition, the shareholders re-appointed Ernst & Young LLP, Chartered Accountants, as auditor of the Company.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected] .For more information on Medicure please visit www.medicure.com .
  • AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets are registered trademarks of Medicure International Inc.Marley Drug is a registered trademark of Medicure Pharma Inc.

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER

Retrieved on: 
Tuesday, May 31, 2022

ZYPITAMAG contributed $1.0 million of revenue for the quarter ended March 31, 2022 compared to $161,000 for the quarter ended March 31, 2021.

Key Points: 
  • ZYPITAMAG contributed $1.0 million of revenue for the quarter ended March 31, 2022 compared to $161,000 for the quarter ended March 31, 2021.
  • The Marley Drug business contributed $1.9 million of revenue during the quarter ended March 31, 2022 compared to $2.1 million for the quarter ended March 31, 2021.
  • Adjusted EBITDA for the three months ended March 31, 2022 was $1.2 million compared to $31,000 for the three months ended March 31, 2021.
  • Cash flows used in operating activities for the quarter ended March 31, 2022 totaled $736,000 compared to $224,000 from operating activities for the quarter ended March 31, 2021.